Literature DB >> 1304218

[Idiopathic proliferative vitreoretinopathy. Activation of microglial cells as the deciding factor].

M Weller1, P Esser, K Heimann, P Wiedemann.   

Abstract

Mononuclear phagocytes are considered pacemakers in the pathogenesis of proliferative vitreoretinopathy (PVR), but their precise biological origin in preretinal PVR traction membranes has remained obscure. This study presents a combined immunohistochemical protocol for the detection of microglial cells, which was applied to 37 membranes of patients with idiopathic and traumatic PVR and with proliferative diabetic retinopathy (PDR). Microglial cells may be labeled by staining for LN-1, ricinus communis agglutinin-(RCA)-1, vimentin, HLA-DR-II, and nucleoside diphosphatase, but are negative for Leu-M1, Leu-M3, EBM-11, von Willebrand factor, CD22, cytokeratin, and glial fibrillary acidic protein (GFAP). Significant proliferation of microglial cells was found in idiopathic PVR while classical macrophages were typical of traumatic PVR. Only rarely were microglial cells detected in PDR. These findings bring into question previous concepts of the pathobiology of idiopathic PVR and support the hypothesis of idiopathic PVR as a specific disease entity.

Entities:  

Mesh:

Year:  1992        PMID: 1304218

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  3 in total

1.  Vitreous IGFBP-3 effects on Müller cell proliferation and tractional force generation.

Authors:  Jeffery L King; Clyde Guidry
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-05       Impact factor: 4.799

2.  The influence of alloxan-induced diabetes on Müller cell contraction-promoting activities in vitreous.

Authors:  Jeffery L King; John O Mason; Samuel C Cartner; Clyde Guidry
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-27       Impact factor: 4.799

3.  Isolation and characterization of vitreous insulin-like growth factor binding proteins.

Authors:  Clyde Guidry; Jeffery L King
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.